JP2011520815A - 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 - Google Patents

精神神経障害治療のためのｎｍｄａ受容体拮抗薬 Download PDF

Info

Publication number
JP2011520815A
JP2011520815A JP2011508724A JP2011508724A JP2011520815A JP 2011520815 A JP2011520815 A JP 2011520815A JP 2011508724 A JP2011508724 A JP 2011508724A JP 2011508724 A JP2011508724 A JP 2011508724A JP 2011520815 A JP2011520815 A JP 2011520815A
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
carbons
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520815A5 (https=
Inventor
デイングルデイーン，レイモンド・ジエイ
トレイネリス，ステイーブン・エフ
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2011520815A publication Critical patent/JP2011520815A/ja
Publication of JP2011520815A5 publication Critical patent/JP2011520815A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011508724A 2008-05-09 2009-05-11 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 Pending JP2011520815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
US61/127,098 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
JP2011520815A true JP2011520815A (ja) 2011-07-21
JP2011520815A5 JP2011520815A5 (https=) 2012-06-21

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508724A Pending JP2011520815A (ja) 2008-05-09 2009-05-11 精神神経障害治療のためのｎｍｄａ受容体拮抗薬

Country Status (16)

Country Link
US (1) US20110160223A1 (https=)
EP (1) EP2296658A4 (https=)
JP (1) JP2011520815A (https=)
KR (1) KR20110016891A (https=)
CN (1) CN102762207A (https=)
AU (1) AU2009244082A1 (https=)
BR (1) BRPI0912362A2 (https=)
CA (1) CA2722776A1 (https=)
CO (1) CO6341558A2 (https=)
EA (1) EA020339B1 (https=)
IL (1) IL208895A0 (https=)
MX (1) MX2010012186A (https=)
NZ (1) NZ589764A (https=)
SG (1) SG195568A1 (https=)
WO (1) WO2009137843A2 (https=)
ZA (1) ZA201007958B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130668A (ja) * 2015-07-06 2022-09-06 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788656A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2963938C (en) * 2014-10-07 2023-10-24 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
WO2019071394A1 (zh) * 2017-10-09 2019-04-18 华南农业大学 一种抗白色念珠菌的新型化合物及其制备方法和应用
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
CA3230601A1 (en) * 2021-09-02 2023-03-09 Dennis Liotta Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS54160389A (en) * 1978-06-06 1979-12-19 Hoechst Ag Novel substituted phenylpiperazine derivative and its manufacture
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
JPS61129167A (ja) * 1984-11-22 1986-06-17 ヘキスト・アクチエンゲゼルシヤフト 新規な置換されたフエニルピペラジン誘導体、それらの製造法およびそれらの用途
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
JP2001507721A (ja) * 1997-10-31 2001-06-12 サントリー株式会社 アリールピペリジノプロパノール及びアリールピペラジノプロパノール誘導体並びにそれらを含む医薬
WO2004035534A2 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue verbindungen mit dopaminerger und/oder serotoninerger aktivität
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2006010968A1 (en) * 2004-07-29 2006-02-02 Richter Gedeon Vegyészeti Gyár Rt. New aryloxy acetic acid amide derivatives
JP2006528236A (ja) * 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク ジプラシドンを用いて認知を増強する方法
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US7022882B2 (en) * 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS54160389A (en) * 1978-06-06 1979-12-19 Hoechst Ag Novel substituted phenylpiperazine derivative and its manufacture
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
JPS61129167A (ja) * 1984-11-22 1986-06-17 ヘキスト・アクチエンゲゼルシヤフト 新規な置換されたフエニルピペラジン誘導体、それらの製造法およびそれらの用途
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
JP2001507721A (ja) * 1997-10-31 2001-06-12 サントリー株式会社 アリールピペリジノプロパノール及びアリールピペラジノプロパノール誘導体並びにそれらを含む医薬
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2004035534A2 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue verbindungen mit dopaminerger und/oder serotoninerger aktivität
JP2006528236A (ja) * 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク ジプラシドンを用いて認知を増強する方法
WO2006010968A1 (en) * 2004-07-29 2006-02-02 Richter Gedeon Vegyészeti Gyár Rt. New aryloxy acetic acid amide derivatives
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEM PHARM BULL, vol. 36, no. 11, JPN6013055772, 1988, pages 4377 - 4388, ISSN: 0002678087 *
INDIAN JOURNAL OF CHEMISTRY, vol. 15, JPN7013002063, 1977, pages 466 - 472, ISSN: 0002678085 *
INDIAN JOURNAL OF CHEMISTRY, vol. 21, JPN7013002060, 1982, pages 914 - 918, ISSN: 0002678084 *
J MED CHEM, vol. 41, JPN6013055775, 1998, pages 658 - 667, ISSN: 0002678088 *
LIFE SCIENCES, vol. 43, JPN6013055770, 1988, pages 263 - 269, ISSN: 0002678086 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130668A (ja) * 2015-07-06 2022-09-06 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
JP7478190B2 (ja) 2015-07-06 2024-05-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法

Also Published As

Publication number Publication date
EA020339B1 (ru) 2014-10-30
EP2296658A4 (en) 2014-01-15
WO2009137843A2 (en) 2009-11-12
EP2296658A2 (en) 2011-03-23
CO6341558A2 (es) 2011-11-21
CA2722776A1 (en) 2009-11-12
ZA201007958B (en) 2011-07-27
BRPI0912362A2 (pt) 2015-10-06
IL208895A0 (en) 2011-01-31
NZ589764A (en) 2012-10-26
SG195568A1 (en) 2013-12-30
AU2009244082A1 (en) 2009-11-12
EA201071291A2 (ru) 2011-04-29
US20110160223A1 (en) 2011-06-30
CN102762207A (zh) 2012-10-31
EA201071291A3 (ru) 2014-02-28
KR20110016891A (ko) 2011-02-18
MX2010012186A (es) 2011-02-22
WO2009137843A9 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
JP2011520815A (ja) 精神神経障害治療のためのｎｍｄａ受容体拮抗薬
EP2170334B1 (en) Nmda receptor antagonists for neuroprotection
US9278943B2 (en) Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2879673B1 (en) 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders
CN107840845B (zh) 胺类化合物的新用途
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
US20140148432A1 (en) Compounds for the Treatment of Neurological Disorders
JP2018527354A (ja) ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
RS55916B1 (sr) Derivati aminociklobutana, metod za dobijanje istih i njihova upotreba kao lekova
US20250129064A1 (en) Prodrugs of 2-bromo-lsd (2-bromolysergic acid diethylamide)
CN110770209B (zh) 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
US20120088800A1 (en) 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS
AU2013203941A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
WO2009085847A1 (en) Tetrahydroindoles having sphingosine-1-phosphate receptor activity
AU2013203908A1 (en) Compounds for the treatment of neurologic disorders
NZ623571A (en) Dosage regimen for an s1p receptor modulator or agonist
HK1240927B (zh) 氨基环丁烷衍生物、其制备方法及其用作药物的用途
HK1211236B (en) 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (s1p) receptor and/or autotaxin (atx) modulators for treating inflammatory and autoimmune disorders
NZ623571B2 (en) Dosage regimen for an s1p receptor modulator or agonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140715